Tokyo, Nov 28, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it has submitted an application for the proton pump inhibitor Pariet (rabeprazole sodium, “rabeprazole”) in Japan seeking a further indication expansion for use in the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy and the approval of a new 5 mg tablet formulation.
Help employers find you! Check out all the jobs and post your resume.
